140 related articles for article (PubMed ID: 25850580)
1. Update in germ cell tumours.
Feldman DR
Curr Opin Oncol; 2015 May; 27(3):177-84. PubMed ID: 25850580
[TBL] [Abstract][Full Text] [Related]
2. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Feldman DR; Iyer G; Van Alstine L; Patil S; Al-Ahmadie H; Reuter VE; Bosl GJ; Chaganti RS; Solit DB
Clin Cancer Res; 2014 Jul; 20(14):3712-20. PubMed ID: 24812411
[TBL] [Abstract][Full Text] [Related]
3. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
[TBL] [Abstract][Full Text] [Related]
4. Intermediate and long-term complications associated with adjuvant chemotherapy for stage I germ cell tumor patients.
Suarez-Ibarrola R; Abufaraj M; Shariat SF
Curr Opin Urol; 2018 Sep; 28(5):485-490. PubMed ID: 30044319
[TBL] [Abstract][Full Text] [Related]
5. Factor V Leiden mutation triggering four major complications to standard dose cisplatin-chemotherapy for testicular seminoma: a case report.
Dieckmann KP; Anheuser P; Gehrckens R; Aries SP; Ikogho R; Hollburg W
BMC Urol; 2015 Mar; 15():21. PubMed ID: 25887618
[TBL] [Abstract][Full Text] [Related]
6. Advanced seminoma and nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.
Schmoll HJ; Osanto S; Kawai K; Einhorn L; Fizazi K
Urology; 2011 Oct; 78(4 Suppl):S456-68. PubMed ID: 21986225
[TBL] [Abstract][Full Text] [Related]
7. Testicular germ-cell cancer.
Horwich A; Shipley J; Huddart R
Lancet; 2006 Mar; 367(9512):754-65. PubMed ID: 16517276
[TBL] [Abstract][Full Text] [Related]
8. IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.
Selfe J; Goddard NC; McIntyre A; Taylor KR; Renshaw J; Popov SD; Thway K; Summersgill B; Huddart RA; Gilbert DC; Shipley JM
J Pathol; 2018 Feb; 244(2):242-253. PubMed ID: 29160922
[TBL] [Abstract][Full Text] [Related]
9. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
10. Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance.
Wermann H; Stoop H; Gillis AJ; Honecker F; van Gurp RJ; Ammerpohl O; Richter J; Oosterhuis JW; Bokemeyer C; Looijenga LH
J Pathol; 2010 Aug; 221(4):433-42. PubMed ID: 20593487
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin resistance in germ cell tumours: models and mechanisms.
Jacobsen C; Honecker F
Andrology; 2015 Jan; 3(1):111-21. PubMed ID: 25546083
[TBL] [Abstract][Full Text] [Related]
12. Mutations of BRAF and RAS are rare events in germ cell tumours.
Sommerer F; Hengge UR; Markwarth A; Vomschloss S; Stolzenburg JU; Wittekind C; Tannapfel A
Int J Cancer; 2005 Jan; 113(2):329-35. PubMed ID: 15386408
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors.
Honecker F; Wermann H; Mayer F; Gillis AJ; Stoop H; van Gurp RJ; Oechsle K; Steyerberg E; Hartmann JT; Dinjens WN; Oosterhuis JW; Bokemeyer C; Looijenga LH
J Clin Oncol; 2009 May; 27(13):2129-36. PubMed ID: 19289622
[TBL] [Abstract][Full Text] [Related]
14. Third-line chemotherapy and novel agents for metastatic germ cell tumors.
Veenstra CM; Vaughn DJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610
[TBL] [Abstract][Full Text] [Related]
15. Role of N-cadherin in proliferation, migration, and invasion of germ cell tumours.
Bremmer F; Schallenberg S; Jarry H; Küffer S; Kaulfuss S; Burfeind P; Strauß A; Thelen P; Radzun HJ; Ströbel P; Honecker F; Behnes CL
Oncotarget; 2015 Oct; 6(32):33426-37. PubMed ID: 26451610
[TBL] [Abstract][Full Text] [Related]
16. Histopathological and molecular features of late relapses in non-seminomas.
Mayer F; Wermann H; Albers P; Stoop H; Gillis AJ; Hartmann JT; Bokemeyer CC; Oosterhuis JW; Looijenga LH; Honecker F
BJU Int; 2011 Mar; 107(6):936-43. PubMed ID: 20955261
[TBL] [Abstract][Full Text] [Related]
17. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
[TBL] [Abstract][Full Text] [Related]
18. Current knowledge of risk factors for testicular germ cell tumors.
Fukawa T; Kanayama HO
Int J Urol; 2018 Apr; 25(4):337-344. PubMed ID: 29345008
[TBL] [Abstract][Full Text] [Related]
19. Current medical management of patients with poor-risk metastatic germ-cell tumors.
Albany C
Curr Opin Urol; 2018 Sep; 28(5):474-478. PubMed ID: 29979236
[TBL] [Abstract][Full Text] [Related]
20. The clinical features and management of testicular germ cell tumours in patients aged 60 years and older.
Wheater MJ; Manners J; Nolan L; Simmonds PD; Hayes MC; Mead GM
BJU Int; 2011 Dec; 108(11):1794-9. PubMed ID: 21627751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
